コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 (daytime cognitive function) and long-term (cardiovascular outcomes).
2 ts of an HLA-DR1 donor also have an impaired cardiovascular outcome.
3 esulted in a noninferior risk of a composite cardiovascular outcome.
4 zing treatment strategies to achieve maximum cardiovascular outcome.
5 SVI for HF hospitalization and the composite cardiovascular outcome.
6 nhibitors have a favorable effect on certain cardiovascular outcomes.
7 ol abuse can also influence both hepatic and cardiovascular outcomes.
8 ter-randomized trials of sodium reduction on cardiovascular outcomes.
9 le targets for prevention to achieve optimal cardiovascular outcomes.
10 insufficient duration to show any effect on cardiovascular outcomes.
11 ill uncertainty about their effects on other cardiovascular outcomes.
12 to steatosis post-LT, patient survival, and cardiovascular outcomes.
13 ver more important to optimize our patients' cardiovascular outcomes.
14 ous cardiac treatments can also benefit some cardiovascular outcomes.
15 ave been maintained and to assess effects on cardiovascular outcomes.
16 ociations between atopic eczema and specific cardiovascular outcomes.
17 s, in addition to CAD and other atheromatous cardiovascular outcomes.
18 xposure has been related to numerous adverse cardiovascular outcomes.
19 fect of increasing atopic eczema severity on cardiovascular outcomes.
20 r risk of amyloidosis, HF, and other adverse cardiovascular outcomes.
21 d clinical profiles, exercise responses, and cardiovascular outcomes.
22 previously shown to be associated with worse cardiovascular outcomes.
23 tcome of interest was reduction in composite cardiovascular outcomes.
24 mized controlled trials (RCTs) that examined cardiovascular outcomes.
25 verity was associated with increased risk of cardiovascular outcomes.
26 ificantly associated with increased risk for cardiovascular outcomes.
27 ited Kingdom, 1979-1998) relating smoking to cardiovascular outcomes.
28 mates of sodium and potassium excretion with cardiovascular outcomes.
29 PM(2.5) species most associated with adverse cardiovascular outcomes.
30 ors have shown neutral or adverse effects on cardiovascular outcomes.
31 a, adding ASV to OMT did not improve 6-month cardiovascular outcomes.
32 race-stratified associations between BP and cardiovascular outcomes.
33 h-sensitivity cardiac troponin I (hsTnI) and cardiovascular outcomes.
34 d is associated with atrial fibrillation and cardiovascular outcomes.
35 ifestyle, and other environmental factors on cardiovascular outcomes.
36 progenitor cells and their impact on adverse cardiovascular outcomes.
37 all aspects of these disparities to improve cardiovascular outcomes.
38 , and shorter LTL is associated with adverse cardiovascular outcomes.
39 ubsequent systemic inflammation, and adverse cardiovascular outcomes.
40 finerenone reduced the composite kidney and cardiovascular outcomes.
41 tion fraction may improve survival and other cardiovascular outcomes.
42 patients with AF and their associations with cardiovascular outcomes.
43 lower risks for physical disability and all cardiovascular outcomes.
44 is managed can have a substantial impact on cardiovascular outcomes.
45 in patients with hypertension for improving cardiovascular outcomes.
46 sed pericardial fat is associated with worse cardiovascular outcomes.
47 ity of control and choice of medications) in cardiovascular outcomes.
48 se cotransporter 2 inhibitors reduce adverse cardiovascular outcomes.
49 tion is linked to impaired lung function and cardiovascular outcomes.
50 s a strong, independent predictor of adverse cardiovascular outcomes.
51 ctly targeting the gut microbiome to improve cardiovascular outcomes.
52 o lower blood pressure (BP) targets improves cardiovascular outcomes.
53 ysfunction, cardiac dysfunction, and adverse cardiovascular outcomes.
54 dels were used to estimate hazard ratios for cardiovascular outcomes adjusted for known predictors, i
55 m Hg on treatment, the risk of the composite cardiovascular outcome (adjusted hazard ratio [HR] 1.14,
56 ers are associated with an increased risk of cardiovascular outcomes after AMI, but little is known a
58 analysis of ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
62 nalysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
63 In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
66 MES randomized clinical trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
67 el data from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
70 FOURIER and ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
71 in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome
74 to assess the benefits of LDL-C lowering on cardiovascular outcomes among individuals with primary e
75 during acute mental stress predicts adverse cardiovascular outcomes among patients with coronary art
76 d benefit of a 10-mm Hg reduction in SBP for cardiovascular outcomes among patients with hypertension
78 association between aromatase inhibitors and cardiovascular outcomes among women with breast cancer i
79 ciation of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence
80 pendently associated with higher risk of the cardiovascular outcome and the kidney outcome, but not w
81 y sought to describe the acute and long-term cardiovascular outcomes and assess the predictors of rec
82 ects of intensive SBP lowering on kidney and cardiovascular outcomes and contrast its apparent benefi
83 vement in the net reclassification index for cardiovascular outcomes and death compared with prediabe
84 PM2.5) are associated with increased risk of cardiovascular outcomes and death, but their association
85 eport the effect of finerenone on individual cardiovascular outcomes and in patients with and without
86 olic volume index (LAESVI) is a predictor of cardiovascular outcomes and is the recommended measureme
87 To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncar
91 sociated with an increased risk of death and cardiovascular outcomes and should merit further attenti
92 f the oft-cited issue of sodium reduction on cardiovascular outcomes and then propose a framework for
95 examined the impact of bariatric surgery on cardiovascular outcomes, and specifically compared the d
97 tional effects of canagliflozin on renal and cardiovascular outcomes are mostly consistent across pat
100 e the individual components of the composite cardiovascular outcome, as well as incident atrial fibri
109 edge repair with the MitraClip in the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Perc
111 e risk of amyloidosis, HF, and other adverse cardiovascular outcomes associated with CTS relative to
112 medical therapy did not significantly affect cardiovascular outcomes at 12 months in patients with AC
113 optimal statin therapy, alirocumab improves cardiovascular outcomes at costs considered intermediate
115 However, somewhat lower risks of specific cardiovascular outcomes, breast cancer, and diabetes wer
116 factor for kidney disease and biomarker for cardiovascular outcomes but long term longitudinal analy
117 on interventions have an uncertain effect on cardiovascular outcomes, but CBT combined with antidepre
119 hibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, wh
120 ixed-dose combination polypill might improve cardiovascular outcomes by increasing prescription rates
121 ortantly, this anatomic approach may improve cardiovascular outcomes by increasing the use of evidenc
122 tudy Outcomes Model 2 (for microvascular and cardiovascular outcomes, C-statistics 0.54-0.62, slopes
123 dvances in care have spurred improvements in cardiovascular outcomes, cardiovascular disease remains
124 with 3) exposure to fertility therapy and 4) cardiovascular outcomes clearly reported; 5) presence of
125 with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 pe
126 finerenone reduced the risk of the composite cardiovascular outcome compared with placebo (hazard rat
127 or cardiovascular events had higher rates of cardiovascular outcomes compared with the primary preven
130 and low CD34+ levels (<Q1) predicted adverse cardiovascular outcomes (death, myocardial infarction, c
131 through 2014, mortality and the incidence of cardiovascular outcomes declined substantially among per
132 p between achieved LDL cholesterol and major cardiovascular outcomes down to LDL-cholesterol concentr
133 To assess the trajectory of respiratory and cardiovascular outcomes during transition to adulthood i
134 In patients at high risk for major adverse cardiovascular outcomes, electronic and biochemical moni
135 increases risks for adverse respiratory and cardiovascular outcomes, especially among certain suscep
136 -REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
137 The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Me
138 e EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
139 ackground In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
140 efits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
141 in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
142 The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Me
144 atment was associated with increased risk of cardiovascular outcomes except for myocardial infarction
145 b as part of the Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in
148 , and management of bleeding in the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation
149 d with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation
151 his was a secondary analysis of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation
152 or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation
154 prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation
155 ialysis-dependent kidney failure (DDKF), and cardiovascular outcomes) for a total of 1131 participant
156 participants, and genetic associations with cardiovascular outcomes from 367 703 participants in UK
158 cardiometabolic risk factors, the effect on cardiovascular outcomes has been less well characterized
159 Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studie
161 ar associations were noted for the composite cardiovascular outcome (HR for LAEDVI, 2.97; P<0.001) an
162 dog ownership was inversely associated with cardiovascular outcomes (HR composite CVD 0.92, 95% CI,
163 ens is associated with unfavorable long-term cardiovascular outcome in KTRs independent of graft loss
164 ity of hypertension and its association with cardiovascular outcomes in 562 patients treated with ibr
165 rdial infarction, stroke, and a composite of cardiovascular outcomes in a large population cohort.
167 other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk
168 , a machine learning technique, to predict 6 cardiovascular outcomes in comparison to standard cardio
169 dependent and additive predictors of adverse cardiovascular outcomes in coronary artery disease patie
170 ty (PA) is inversely associated with adverse cardiovascular outcomes in healthy populations, but the
171 etabolite trimethylamine N-oxide (TMAO) with cardiovascular outcomes in hemodialysis patients and ass
172 V) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HF patients with
173 importance of 17 risk factors for death and cardiovascular outcomes in individuals with type 1 diabe
174 n trial CREDENCE (Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Ne
177 lowering to a 10-mm Hg reduction in SBP for cardiovascular outcomes in patients with a history of st
178 investigated the risk of bleeding and major cardiovascular outcomes in patients with atrial fibrilla
179 receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney
180 is associated with a higher risk of adverse cardiovascular outcomes in patients with coronary artery
181 the alpha-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart
182 ME) study was the first trial that evaluated cardiovascular outcomes in patients with diabetes with t
183 assessing the effects of SGLT2 inhibitors on cardiovascular outcomes in patients with HFrEF with or w
184 most important predictors for mortality and cardiovascular outcomes in patients with type 1 diabetes
185 , patients in SAVOR-TIMI 53 (Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes
186 rtant risk factor for graft loss and adverse cardiovascular outcomes in pediatric kidney transplantat
187 e peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes a
188 mental illness (SMI), but efforts to predict cardiovascular outcomes in these patients have been lack
190 sociated with residual risk of mortality and cardiovascular outcomes in those with T1DM compared with
191 factors related to excess risk of death and cardiovascular outcomes in type 1 diabetes mellitus have
192 udinal strain (GLS) is prognostic of adverse cardiovascular outcomes in various patient populations,
193 vely investigated CR and longer-term adverse cardiovascular outcomes in women with and with no obstru
194 ired microvascular function predicts adverse cardiovascular outcomes in women with signs and symptoms
197 mnant-C, but not LDL-C, were associated with cardiovascular outcomes independent of other risk factor
199 BNP had similar predictive value for adverse cardiovascular outcomes, irrespective of AF status.
202 thetic nervous system signalling to systemic cardiovascular outcomes is reduced in normotensive pregn
204 r systolic BP associated with higher risk of cardiovascular outcome, kidney outcome, and mortality, i
205 ambulatory BP monitoring are associated with cardiovascular outcomes, kidney outcomes, and mortality,
206 ntial benefits of statins between cancer and cardiovascular outcomes may provide a unique opportunity
207 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically
208 ices of angina, cell-based therapies improve cardiovascular outcomes (mortality/MACE) in patients wit
209 which may account in part for the beneficial cardiovascular outcomes observed in the EMPA-REG OUTCOME
210 We included randomised controlled trials of cardiovascular outcomes of an LDL cholesterol-lowering d
211 of the first 10 trial emulations, evaluating cardiovascular outcomes of antidiabetic or antiplatelet
212 and screened for eligibility, four trials of cardiovascular outcomes of GLP-1 receptor agonists were
216 continue into adulthood and lead to adverse cardiovascular outcomes or other obesity-related morbidi
219 Americas ( P=0.12 for difference in primary cardiovascular outcome; P=0.20 for difference in total m
220 erol concentration at 4 weeks and subsequent cardiovascular outcomes (primary endpoint was the compos
221 ean follow-up of 3.8 years, the incidence of cardiovascular outcomes ranged from 75 (ACC/AHA) to 298
225 nt systolic and diastolic blood pressure and cardiovascular outcomes remains unclear and has been com
227 tic methods, and current use and examples of cardiovascular outcomes research that apply qualitative
229 5 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition i
231 tor evolocumab in the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibition i
232 ascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition i
234 t hoc analysis of the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition i
235 Background of Aspirin), and FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition i
236 1,204 patients enrolled in FOURIER (Further Cardiovascular Outcomes Research With PCSK9 inhibitors i
238 dentify priorities and barriers to important cardiovascular outcomes research; and (3) define future
239 ular disease from the FOURIER trial (Further Cardiovascular Outcomes Researh With PCSK9 Inhibition in
240 Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [LEADER]; NCT01179048).
241 Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) participants, by HF hist
242 Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation [L
244 The elevated hazard ratios observed for the cardiovascular outcomes should be corroborated in future
245 the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarct
246 ol-lowering agents currently being tested in cardiovascular outcome studies are bempedoic acid, an ad
247 es in oncology, a large prospective clinical cardiovascular outcome study investigating the BET inhib
248 iabetes had roughly 40% greater reduction in cardiovascular outcomes than controls, and patients with
249 was associated with a lower risk of adverse cardiovascular outcomes than usual care among patients w
250 te setting resulted in a risk of a composite cardiovascular outcome that was lower than the risk amon
251 tudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of d
252 mprovement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid h
253 lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/met
255 doses of evolocumab being studied in a large cardiovascular outcomes trial suppress PCSK9 levels and
256 ovascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants
257 luation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial), a double-blind, placebo-
258 hibitor dapagliflozin in the DECLARE-TIMI 58 cardiovascular outcomes trial, which included patients w
259 lar safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in
261 at have emerged from the regulatory-mandated cardiovascular outcome trials for all sodium-glucose cot
263 these medications, highlighting recent large cardiovascular outcome trials investigating these therap
265 ly when designing, conducting, and analyzing cardiovascular outcome trials of glucose-lowering agents
266 tions for future regulatory guidance and for cardiovascular outcome trials of glucose-lowering therap
267 -analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with
268 tion was comparable with the benefit seen in cardiovascular outcome trials of SGLT2i versus placebo,
273 e a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.
278 espectively, have published final results of cardiovascular outcomes trials in patients with clinical
279 ped within 3 large ongoing influenza vaccine cardiovascular outcomes trials to determine the potentia
280 integrates these data with results of recent cardiovascular outcomes trials, and discusses clinical a
281 , and describe the ongoing influenza vaccine cardiovascular outcomes trials, highlighting important l
282 that interfere with IL-1 action can improve cardiovascular outcomes, ushering in a new era of anti-i
283 relationships between circulating lipids and cardiovascular outcomes using a Mendelian randomization
284 y, and analyzed the association of TMAO with cardiovascular outcomes using Cox models adjusted for po
285 and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%).
287 ity therapy increase the risk of longer term cardiovascular outcomes?" We included: 1) human studies;
290 diastolic and systolic indices, and adverse cardiovascular outcomes were assessed in adjusted models
291 L + Z intake, and elevated risks of certain cardiovascular outcomes were associated with a higher in
299 inerenone reduced incidence of the composite cardiovascular outcome, with no evidence of differences
300 al infarction is an independent predictor of cardiovascular outcomes, yet little is known about facto